Background-Photodynamic therapy (PDT) is a technique for producing localised tissue necrosis with light after prior administration of a photosensitising drug. There is some selectivity of uptake of photosensitisers in malignant tissue, although this is difficult to exploit. Full thickness necrosis in normal and neoplastic colon heals without perforation because of a lack of effect on collagen, making local cure a possibility. The experiments described here aim to establish whether these conclusions are also valid for bronchial tumours. Methods-In pharmacokinetic studies normal rats were given 5 mg/kg of the photosensitiser aluminium sulphonated phthalocyanine (AlSPc) intravenously and killed up to one month later. The distribution of AlSPc in the trachea was measured by chemical extraction and fluorescence microscopy. In subsequent experiments sensitised animals were treated with light delivered to the tracheal mucosa through a thin flexible fibre and the resultant lesions were studied for their size, mechanical strength, and healing. A series of resected human bronchial carcinomas were examined histologically for their collagen content.
therapy (PDT) is a technique for producing localised tissue necrosis with light after prior administration of a photosensitising drug. There is some selectivity of uptake of photosensitisers in malignant tissue, although this is difficult to exploit. Full thickness necrosis in normal and neoplastic colon heals without perforation because of a lack of effect on collagen, making local cure a possibility. The experiments described here aim to establish whether these conclusions are also valid for bronchial tumours. Methods-In pharmacokinetic studies normal rats were given 5 mg/kg of the photosensitiser aluminium sulphonated phthalocyanine (AlSPc) intravenously and killed up to one month later. The distribution of AlSPc in the trachea was measured by chemical extraction and fluorescence microscopy. In subsequent experiments sensitised animals were treated with light delivered to the tracheal mucosa through a thin flexible fibre and the resultant lesions were studied for their size, mechanical strength, and healing. A series of resected human bronchial carcinomas were examined histologically for their collagen content. Results-The tracheal concentration of AlSPc in normal rats was maximum 1-20 hours after administration. Fluorescence microscopy revealed that most was in the perichondrium and submucosal stroma, with little in the cartilage. Light exposure showed necrosis of the soft tissues which healed by regeneration, but no effect on cartilage and no reduction in the mechanical strength of the trachea at any stage. Histological examination of resected human bronchial carcinomas showed more collagen in the tumour areas than would be found in normal regions. Conclusions-PDT leads to necrosis of the soft tissues of the normal trachea but there is complete healing by regeneration, no risk of perforation (due to collagen preservation), and no effect on cartilage. Human bronchial carcinomas apparently contain more collagen than normal bronchi which may give protection against perforation following necrosis induced by PDT. PDT may have a role in eradicating small volumes of tumour tissue in situ and could be valuable for treating (1) small carcinomas in patients unfit for resection, (2) tumour remaining after surgical resection, (3) stump recurrences, or (4) to prolong palliation of tumours after debulking with the NdYAG laser. (Thorax 1993; 48:474-480) Only a minority of bronchial carcinomas are potentially curable by surgical resection and no real advances in cure rates are being achieved by radiotherapy or chemotherapy. New therapies therefore merit careful consideration. We have studied the potential role of photodynamic therapy (PDT) in the treatment of bronchial carcinoma and assessed its safety and efficacy in an animal model.
PDT is a technique for producing local tissue necrosis with light after prior administration of a photosensitising drug. The mechanism is photochemical rather than thermal, the active intermediate agent is considered to be singlet oxygen,' so the intensity of light required is much lower than that used with high power instruments such as the neodymium yttrium aluminium garnet (NdYAG) laser.2 The technique has attracted considerable interest because photosensitisers are retained in malignant tissues with some selectivity compared with the adjacent normal tissues in which the tumour arose. The degree of selectivity, however, has been overemphasised in past publications and it is very difficult to limit damage to tumour areas when both tumour and normal tissue are exposed to the same light dose.3
Haematoporphyrin derivative (HpD), or its partly purified form Photofrin (Quadralogic Technology, Vancouver, Canada), are the most commonly used photosensitisers for clinical PDT but they have certain disadvantages. Both are ill defined mixtures of porphyrins and leave patients sensitive to sunlight for several weeks after administration. Aluminium sulphonated phthalocyanine (AlSPc) is more promising and has been used experimentally in this centre since 1984. It is relatively easy to synthesise, chemically stable, water soluble, and causes less photosensitivity to sunlight.5 Red light is used for PDT as it penetrates tissue much better than other visible wavelengths but is still able to activate the photosensitisers. AlSPc has the additional advantage that it absorbs red light much better than HpD. Following the finding that AlSPc enabled the photodestruction of sensitised cells in vitro,6 the uptake, distribution and biological effects of this sensitiser were investigated in vivo in a number of normal and malignant tissues.7-" AlSPc has proved to be a more efficient sensitiser than HpD although its selectivity of tumour uptake is the same.7
There have been few reports of experiments with PDT on bronchial tumours in animals,'2 and none on its effects on normal bronchi although detailed studies have been carried out in the gastrointestinal and urinary tracts.' "-'s Most of the data on uptake of photosensitisers by bronchial tumours are clinical and based on fluorescence excited by ultraviolet (UV) light and visualised by bronchoscopy.16 UV light only penetrates a fraction of a millimetre into tissue so the technique only looks at surface changes, but as far as can be judged from these data, the selectivity of uptake of the sensitisers in bronchial tumours is likely to be comparable to that in colonic tumours. If there is to be any prospect of eradicating small bronchial tumours by PDT it is therefore essential to understand the effects of PDT on normal bronchi.
The main conclusions from the experimental work carried out on the rat colon were that necrosis produced by PDT healed safely in normal and neoplastic areas without any reduction in the mechanical strength of the bowel wall because of a lack of any effect of PDT on collagen. The aim of the present work was to establish whether similar conclusions could be drawn about the effect of PDT on normal airways, and to look at the collagen content of bronchial cancers to assess whether treatment of these tumours with PDT is likely to cause any weakness in the bronchial wall. Experiments were carried out on the trachea of normal rats to study the distribution of the photosensitiser and the response to light. Lesions produced by PDT were compared with those produced thermally. In addition the collagen content of non-small cell human lung cancers was examined in resected specimens.
Methods

IN VIVO STUDIES ON THE NORMAL RAT TRACHEA
The distribution of photosensitiser in the normal rat trachea at a range of times after administration was studied by a chemical extraction technique and fluorescence microscopy. The effects of PDT were produced by exposing the trachea of sensitised animals to red light. Lesions of similar size were produced by low power hyperthermia in unsensitised animals and the mechanical strengths of the two types of lesion were compared with the strength of normal trachea. Similar lesions (PDT only) were produced in a separate series of experiments for assessment of healing.
Photosensitiser and animals
AlSPc (Ciba-Geigy) was dissolved in normal saline at a concentration of 2 mg/ml and the solution was stored in the dark. All in vivo experiments were performed on adult male Wistar rats (400-800 g) sensitised with a 5 mg/kg intravenous dose of AlSPc. All injections and surgical procedures were performed under general anaesthesia induced by intramuscular Hypnorm (fentanyl and fluanisone).
Assay ofAlSPc by chemical extraction Animals were killed at times from five minutes to one month after sensitisation and the relevant tissues removed and stored at -40C until required for assay. AlSPc levels were determined in both lung and trachea. At least three animals were used for each data point.
Thawed tissues were assayed with an alkaline extraction technique.'7 Briefly, wet tissue was treated with 0-1 moHl NaOH in a ratio of 0-1 g:10 ml. Samples were then placed in a water bath at 50°C for four hours with regular agitation and AlSPc concentrations in the supernatant were determined with a fluorometric assay by comparison of fluorescence with that from a standard curve produced using unsensitised tissue and known quantities of sensitiser. The spectrofluorimeter (Perkin-Elmer LS-5 Luminescence Spectrofluorimeter) was set to excite at 604 nm and to detect at 673 nm (10 nm slit widths) with a filter to remove scattered light below 645 nm. Results were expressed as jg/g wet tissue.
Microscopic distribution ofAlSPc Animals were killed at times from five minutes to four hours after sensitisation and the trachea removed and immediately snap frozen. To preserve cellular integrity samples were frozen with isopentane cooled in liquid nitrogen. Serial sections were then prepared, one section being kept frozen while the adjacent section was fixed and stained with haematoxylin and eosin. Cellular detail could thus be observed under a light microscope with the haematoxylin and eosin sections and correlated with the fluorescence of the unstained sections seen with a charged coupled device imaging system (Wright Instruments, Cambridge). The charged coupled device allowed quantitative fluorescence imaging of AlSPc in tissues. Fluorescence was excited with an 8 mW helium neon laser operating at 632-8 nm and detected in the range 660-700 nm as previously described." Control sections were examined to quantify and correct for autofluorescence from unsensitised tissues.
Photodynamic therapy Photodynamic therapy of the normal rat trachea was carried out under general anaes- Energy (joules) Figure 3 Mean (SD) diameter ofPDT damage to the trachea offive animals as a function of the applied energy. All treatments were at one hour after sensitisation with 5 mglkg using a power of 100 mW tip just touched the mucosa on the opposite side of the trachea. Red light (675 nm) was produced by a copper vapour pumped dye laser (Oxford Lasers, Oxford) and total energies of 10-100 J (100 mW for 100-1000 seconds) were applied (one lesion per animal). The laser power used was 100 mW as preliminary experiments had shown that this was the highest power that could be used without causing charring at the fibre tip. The surgical wound was repaired and the animal allowed to recover. Three aspects of the response to PDT were studied: (1) to correlate the size of the lesion with the applied energy, energies from 10-100 J were used (five animals for each energy), animals were killed 72 hours after light exposure, and the diameter of the PDT lesion was measured macroscopically on the fresh specimen; (2) for histological examination (100 J lesions only) animals were killed at times from two hours to three months after light exposure, the trachea was removed and opened, the PDT lesion identified, and the specimen trimmed and fixed in formalin; (3) to test tracheal compliance and bursting pressure 24 hours after light exposure (described below) the mechanical -*--Untreated Tumour necrosis could be produced with bronchoscopic therapy but a "toilet" bronchoscopy was required a few days after the initial treatment to remove the dead tissue and associated secretions. More seriously, oedema in the treated tumour could convert partial bronchial obstruction to complete obstruction which could be life threatening if there was no adequately ventilated lung tissue elsewhere. In addition, in one of these early reports two of six patients with advanced cancers died of massive secondary haemorrhage six and 11 days after treatment,18 and most subsequent reports of treatment of advanced tumours have included similar mortalities. There is unlikely to be any role for PDT as the primary treatment for advanced bronchial cancers; endoscopic recanalisation of bronchi obstructed by exophytic tumour is carried out much more safely and effectively with the NdYAG laser. Palliative recanalisation can usually be completed in one treatment under general anaesthesia without the need for a "clean up" bronchoscopy or the problems of delayed haemorrhage or sensitisation of skin to sunlight.2
With small tumours, however, the situation is completely different. In the same study that reported fatal haemorrhage after PDT in two advanced cancers there was a complete response to treatment (no tumour visible at follow up bronchoscopy) with no complications in five cases of early cancer.18 Other groups have obtained similar results with early cancers not recurring at up to three years.2' 22 It is easy to destroy a small volume of almost any solid tumour by PDT." What matters to a patient is whether that tumour can be destroyed safely and completely in the tissue where it arises. The effect of treatment and subsequent healing on immediately adjacent normal tissue must be understood. The purpose of this paper is to understand what PDT does to normal bronchial tissue and to suggest the maximum diameter of bronchial tumour which might be suitable for PDT. Such studies have not been reported previously.
The results show that full thickness necrosis produced by PDT in the rat trachea heals safely with no cartilage damage or reduction in bursting pressure, so it is unlikely that PDT will cause perforation or collapse of normal major airways. In contrast, thermal lesions damage cartilage and reduce the strength of the trachea. It is therefore potentially dangerous to treat normal tissues with the NdYAG laser, which makes the two laser techniques complementary. The NdYAG is better for palliative debulking of large tumours, while PDT is better for ablating small cancers in their entirety when some normal areas will inevitably be exposed to treatment. Care must be taken, however, to ensure that the power of the laser used for PDT is not sufficient to cause thermal effects such as probably occurred in the development of tracheo-oesophageal fistulae after PDT to oesophageal tumours, a complication that the experimental data suggest should not be experienced after PDT.'4
The purpose of the present experiments was to understand the nature of damage to the airways caused by PDT rather than to optimise dosimetry, so the experiments were carried out at a time when the tissue concentration of sensitiser was at its highest (one hour after administration). Most studies in solid tumours suggest that the maximum ratio of tumour to normal tissue concentration of sensitiser occurs 24-48 hours after sensitisation which is why this time interval is often used clinically, although the tumour: normal ratio is seldom more than 3: 1,'14 [25] [26] [27] and it is extremely difficult to exploit this ratio to achieve truly selective tumour necrosis. Better selectivity with a shorter time interval and less skin sensitivity may be possible with the new sensitiser precursor, 5-amino laevulinic acid (ALA). 28 The possibility of delayed secondary haemorrhage resulting from PDT of advanced bronchial cancers is extremely worrying. 18 20 This has been addressed in colonic cancers of rats treated with PDT; three of nine tumours over 2 cm in diameter, but none of 24 smaller lesions, showed evidence of delayed haemorrhage.3 The main feature of the lesions that bled was that they had been substantially undertreated (margin between necrotic and viable areas lying in tumour tissue), confirming that it is wiser to limit PDT to small lesions. Treatment of full thickness lesions with PDT will require extreme care. The size of the tumour will always be a limiting factor because of the risk of secondary haemorrhage but, even for relatively small tumours, spontaneous breaches of the bronchial wall may occur such as the development of tracheo-oesophageal fistulae, so there is nothing "absolute" about the collagen bridge across the tumour and the risk would have to be assessed carefully in every case.
These results make it feasible to speculate on how PDT may be clinically useful. The most likely situation is with a small volume of tumour of definable extent in a patient unsuitable for surgery. PDT after surgery might kill any tumour cells left in the resection margin and so prevent stump recurrence or it could be used to treat stump recurrences. Another possibility would be to treat the base of exophytic tumours debulked with the NdYAG laser. This could prolong the relatively short period of remission of symptoms achieved with the NdYAG alone. One study reported that PDT applied before surgery may reduce the extent of resection required so that an otherwise inoperable patient may become operable, although this might lead to the problems mentioned above associated with partial necrosis of cancers.2' Like all laser therapy PDT is a local treatment and, although the photosensitiser is distributed widely, there will only be a biological effect where there is also therapeutic light. For there to be any prospect of cure it is essential to know how far the tumour extends, both in depth and in local spread along the bronchial lumen, and to be able to deliver an adequate light dose to all relevant areas both on and below the mucosal surface. 
